Premium
Cancer proteomics
Author(s) -
Tan Hwee Tong,
Lee Yie Hou,
Chung Maxey C.M.
Publication year - 2012
Publication title -
mass spectrometry reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 126
eISSN - 1098-2787
pISSN - 0277-7037
DOI - 10.1002/mas.20356
Subject(s) - proteomics , cancer , computational biology , biomarker discovery , biomarker , proteome , chemistry , carcinogenesis , bioinformatics , biology , medicine , biochemistry , gene
Cancer presents high mortality and morbidity globally, largely due to its complex and heterogenous nature, and lack of biomarkers for early diagnosis. A proteomics study of cancer aims to identify and characterize functional proteins that drive the transformation of malignancy, and to discover biomarkers to detect early‐stage cancer, predict prognosis, determine therapy efficacy, identify novel drug targets, and ultimately develop personalized medicine. The various sources of human samples such as cell lines, tissues, and plasma/serum are probed by a plethora of proteomics tools to discover novel biomarkers and elucidate mechanisms of tumorigenesis. Innovative proteomics technologies and strategies have been designed for protein identification, quantitation, fractionation, and enrichment to delve deeper into the oncoproteome. In addition, there is the need for high‐throughput methods for biomarker validation, and integration of the various platforms of oncoproteome data to fully comprehend cancer biology. © 2012 Wiley Periodicals, Inc. Mass Spec Rev 31:583–605, 2012